Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Dermata Therapeutics, Inc.

Accession: 0001493152-26-037124

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0001853816

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001853816

0001853816

2026-08-11

2026-08-11

0001853816

DRMA:CommonStockParValue0.0001PerShareMember

2026-08-11

2026-08-11

0001853816

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

2026-08-11

2026-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 11, 2026

DERMATA

THERAPEUTICS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40739

86-3218736

(State

or other jurisdiction

(Commission

(IRS

Employer

of

incorporation)

File

Number)

Identification

No.)

3525

Del Mar Heights Rd., #322

San

Diego, CA

92130

(Address

of principal executive offices)

(Zip

Code)

(858)

800-2543

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, par value $0.0001 per share

DRMA

The

Nasdaq Capital Market

Warrants,

exercisable for one share of Common Stock

DRMAW

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item

2.02. Results of Operation and Financial Condition.

On

August 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding

its results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished

under Item 2.02 as Exhibit 99.1.

The

information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”

for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange

Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange

Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference

into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such

filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated August 11, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026”

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DERMATA

THERAPEUTICS, INC.

Dated:

August 11, 2026

By:

/s/

Gerald T. Proehl

Name:

Gerald

T. Proehl

Title:

President,

Chairman and Chief Executive Officer

-3-

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Dermata

Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

-

Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026

–

-

Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN

DIEGO, CA, August 11, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”),

a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the

second quarter ended June 30, 2026.

“Over

the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,”

commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution

across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect

to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped

‘white space’ to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues

in the near future while continuing to build long-term value for our shareholders,” continued Mr. Proehl. “Looking ahead,

we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the

foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement,

and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated

skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to

come,” concluded Mr. Proehl.

Corporate

Highlights

● Attended

first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand.

In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially

launch the Tome brand and provided attendees with more information on the upcoming launch

of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa,

and wellness professionals with over 400+ brands in attendance.

● Began

social media campaign for its new skincare brand, Tome. The Company recently unveiled

the Tome brand’s official social media presence as part of the Company’s broader

commercial launch strategy. These efforts are designed to increase brand awareness, engage

prospective consumers, and support the successful ecommerce launch of the Company’s

first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.

Anticipated

Upcoming Milestones

● Launch

first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on

August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational

Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome

Foundational Treatment can be the base of any skincare routine, designed to renew the appearance

of the skin and simplify skincare with a once-weekly application.

● Continue

development of a second DTC product. The Company is also working on its second skincare

product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected

to launch sometime after its Foundational Treatment.

Second

Quarter 2026 Financial Results

As

of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1

million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations,

and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects

its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.

Research

and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30,

2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company’s decision to prioritize

the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended

June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company

reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development

expenses will continue to decrease compared to prior periods.

Selling,

general and administrative expenses were $2.8 million for the quarter ended June 30, 2026, compared to $1.2 million for the quarter ended

June 30, 2025. The increase in selling, general and administrative expenses was primarily attributable to $0.7 million of increased legal

fees, an increase of $0.6 million of marketing and other commercialization expenses, and an increase of $0.3 million of employee compensation

attributable to a reallocation of employee efforts from research and development activities toward pre-commercial activities in anticipation

of the Company’s first product launch.

About

Dermata Therapeutics

Dermata

Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development

to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing

a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first

product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more

information, or to join our mailing list, please visit http://www.dermatarx.com/.

About

Tome

Tome

is Dermata’s new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal

meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in

science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris,

a wild harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are compelled

by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify

existing skincare routines with essential ingredients that deliver results, without the recovery associated with in-office treatments.

Dermata expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with additional product launches planned

to follow. Start your skincare story at www.tomeskincare.com.

Forward-Looking

Statements

Statements

in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s

current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown

risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to

prioritize DTC and OTC skincare products; the anticipated benefits of Dermata’s strategic shift to prioritize DTC and OTC skincare

products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer

markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Foundational Treatment;

the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company’s

products and their ability to generate revenue for the Company; the Company’s expectations with regard to current cash and cash

equivalents and the amount of time it will fund operations; and other factors described in the Company’s filings with the Securities

and Exchange Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,”

“should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,”

“expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential”

and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and

expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in

any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization.

For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You

are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is

made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified

in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect

events or circumstances after the date hereof, except as required by law.

DERMATA

THERAPEUTICS, INC.

Balance

Sheets

In thousands USD

June 30, 2026

December 31, 2025

(unaudited)

Assets

Cash and cash equivalents

$ 4,413

$ 7,522

Prepaid expenses and other current assets

594

342

Inventories

150

-

Non-current assets

164

-

Total assets

5,321

7,864

Liabilities

Accounts payable

1,120

461

Accrued liabilities

713

1,180

Total liabilities

1,833

1,641

Equity

3,488

6,223

Total liabilities and equity

$ 5,321

$ 7,864

DERMATA

THERAPEUTICS, INC.

Statements

of Operations

(unaudited)

Quarter Ended June 30,

Six Months Ended June 30,

In thousands, except share and per share data

2026

2025

2026

2025

Operating expenses

Research and development (1)

$ 213

$ 618

$ 596

$ 1,899

Selling, general and administrative (1)

2,801

1,155

4,344

2,214

Total operating expenses

3,014

1,773

4,940

4,113

Loss from operations

(3,014 )

(1,773 )

(4,940 )

(4,113 )

Interest income

47

72

125

108

Net loss

$ (2,967 )

$ (1,701 )

$ (4,815 )

$ (4,005 )

Net loss per common share, basic and diluted

$ (0.74 )

$ (1.66 )

$ (1.22 )

$ (5.18 )

Weighted average common shares outstanding, basic and diluted

4,022,143

1,026,506

3,940,983

772,397

(1) Includes the following stock-based compensation expense

Research and development

$ 4

$ 8

$ 18

$ 16

Selling, general and administrative

$ 38

$ 31

$ 67

$ 61

Investor

Contact:

Cliff

Mastricola

Investor

Relations

cmastricola@dermatarx.com

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4168 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 11, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 11, 2026

Entity File Number

001-40739

Entity Registrant Name

DERMATA

THERAPEUTICS, INC.

Entity Central Index Key

0001853816

Entity Tax Identification Number

86-3218736

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

3525

Del Mar Heights Rd.

Entity Address, Address Line Two

#322

Entity Address, City or Town

San

Diego

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92130

City Area Code

(858)

Local Phone Number

800-2543

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

true

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

DRMA

Security Exchange Name

NASDAQ

Warrants, exercisable for one share of Common Stock

Title of 12(b) Security

Warrants,

exercisable for one share of Common Stock

Trading Symbol

DRMAW

Security Exchange Name

NASDAQ

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_WarrantsExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: